GlassScriptPhysician profile
Maridith Hollis
NPI 1730612086
$17,121.12
in general payments reported to CMS, 2019-2025
17 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.85 · 2020: $299 · 2021: $103 · 2022: $495 · 2023: $613 · 2024: $789 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $3,013 · Consulting Fee: $1,600 · Travel and Lodging: $546 · Education: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,830.00 |
| Food and Beverage | $3,012.74 |
| Consulting Fee | $1,600.00 |
| Travel and Lodging | $546.28 |
| Education | $138.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $14,129.77 | 2020-2025 | Lybalvi, Aristada, Vivitrol |
| E.R. Squibb & Sons, L.L.C. | $519.10 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $398.86 | 2020-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Indivior INC. | $324.72 | 2022-2025 | Sublocade, Perseris |
| Teva Pharmaceuticals USA, INC. | $319.72 | 2022-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $233.71 | 2019-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $230.21 | 2021-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $186.85 | 2022-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.84 | 2021-2025 | Caplyta |
| Allergan, INC. | $151.58 | 2019-2020 | |
| Abbvie INC. | $150.92 | 2021-2024 | |
| Dendreon Pharmaceuticals LLC | $149.81 | 2023 | Provenge |
| Lundbeck LLC | $48.16 | 2020-2025 | Abilify Asimtufii, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $41.39 | 2019 | |
| Shire North American Group INC | $26.01 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $22.68 | 2024 | Brixadi |
| Adlon Therapeutics L.P. | $14.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maridith Hollis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.